IRCT20170912036157N1 IRCT 2019-07-30 Dean of Research, Rajaie Cardiovascular Medical and Research Center Effects of dexmedetomidine drug in heart surgery Studying the effects of dexmedetomidine on clinical outcomes and renal function after heart surgery 2017-03-20 anticipated 88 Complete https://irct.ir/trial/38626 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: For randomization, researchers use the Stratified Block randomization method and randomize blocks of 3 to 4 people, and the Random Number Generator as the randomization tool. The method of making random sequences is also stratified according to the inotropic drug intake. To conceal the study from the patient and the main physician of the study (double-blind), the allocation of subjects and drugs in the two groups is done by a trained anesthetic technician that records all the cases initially and the final evaluator of the patient has no information on the type of the prescribed drug. Finally, the statistical information of the two groups is given to the analyst, which is not blind to the groups, Blinding description: Patients are unaware of the groups they were allocated into. They receive the medication during anesthesia. Assessment of the target outcomes are performed with the trained nursing staff who are unaware of the groups. Outcome assessors who fill the questionnaires are not informed regarding the patient allocation. 2-3 Condition 1: Coronary artery bypass grafting. Condition 2: Aneurysms of the cardiac arteries. Intervention 1: Intervention group: High-dose Pfizer company dexmedetomidine (0.75 ug/kg/hr) once from anesthesia induction till the end of operation. Intervention 2: Control group: Low dose Pfizer company dexmedetomidine (0.5 ug/kg/hr) once from anesthesia induction till the end of operation. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information.